Servier appoints David Lee to executive committee

French independent pharma company Servier says it has appointed David Lee to its executive committee as executive vice president for the United States, effective January 1, 2025.

Mr Lee has held the position of chief executive (CEO) of Servier Pharmaceuticals in the USA since the creation of this subsidiary in 2018. Under his leadership, it has become the group’s leading entity with five oncology drugs. Mr Lee will continue to lead Servier’s activities in the USA and will contribute, as a member of the executive committee, to the definition and implementation of the group’s global strategy.

A recognized leader in the pharmaceutical industry, he has held senior positions at Baxalta and Swiss pharma giant Novartis (NOVN: VX). Before joining Servier, Mr Lee was the global head of the Rare Diseases and Oncology franchises at Shire – which was acquired by Japan’s Takeda (TYO: 4502) – where he oversaw cross-functional leadership teams responsible for strategy, marketing, business development, R&D, and support functions. He played a key role in Servier’s acquisition of Shire’s oncology portfolio and later the oncology division of Agios.